Thinly traded nano cap Akers Biosciences (AKER +24.6%) is, yet another, tiny medical company jumping on the COVID-19 bandwagon with its announced license deal with Premas Biotech for a coronavirus vaccine candidate.
Under the terms of the agreement, Akers will
acquire Cystron Biotech LLC (the rights holder?) for $1M upfront plus
622,756 shares of common stock (or equivalents) and a royalty on net
sales. It will also make additional cash and stock payments to the
sellers of Cystron Biotech upon the achievement of certain milestones,
along with a change of control. It will also make cash payments to
Premas if certain milestones are achieved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.